Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

NinePoint Medical Inc.

Apr 2012
A developer of medical devices for in vivo pathology, NinePoint Medical Inc. of Cambridge, Mass., has initiated a clinical trial to evaluate high-resolution optical imaging of Barrett’s esophagus, a common precursor to esophageal cancer, using its Nvision VLE imaging system. The system received 501(k) clearance from the FDA in January. The single-arm open-label observational trial is designed to evaluate the system’s performance in visualizing subsurface tissue in patients undergoing esophagogastroduodenoscopy for suspected or confirmed Barrett’s esophagus. It is expected to enroll about 100 patients at five leading medical centers worldwide. Commercial launch is planned for 2013.

AmericasBiophotonicsBusinessesophageal cancerFDAimagingimaging of Barretts esophagusMassachusettsNinePoint MedicalNvision VLE imaging systemNvision VLE imaging system clinical trialopticsRapidScanUS Food and Drug Administration

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media
x Subscribe to BioPhotonics magazine - FREE!